ECSP066566A - Formas de dosificación farmacéutica de liberación extendida - Google Patents

Formas de dosificación farmacéutica de liberación extendida

Info

Publication number
ECSP066566A
ECSP066566A EC2006006566A ECSP066566A ECSP066566A EC SP066566 A ECSP066566 A EC SP066566A EC 2006006566 A EC2006006566 A EC 2006006566A EC SP066566 A ECSP066566 A EC SP066566A EC SP066566 A ECSP066566 A EC SP066566A
Authority
EC
Ecuador
Prior art keywords
dosage forms
venlafaxine
pharmaceutical dosage
extended
liberation
Prior art date
Application number
EC2006006566A
Other languages
English (en)
Inventor
Angela Potts
Nicholas Heaton
Ian Armstrong
James Andrew Provost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34354596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066566(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066566A publication Critical patent/ECSP066566A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona con formas novedosas de dosificación farmacéutica de liberación extendida para drogas oralmente suministradas a mamíferos, por ejemplo humanos. Más particularmente, esta invención se relaciona con formas de dosificación novedosas de drogas solubles en agua tal como venlafaxina, formas enantioméricas (R o S) de venlafaxina, metabolitos de venlafaxina tales como desmetil venlafaxina (ODV) o las formas enantioméricas (R o S) de dichos metabolitos cuyas formas de dosificación tienen un perfil de liberación extendido cuando son tomadas oralmente. Esta invención también suministra procesos para preparar tales formas de dosificación y métodos para utilizarlas.
EC2006006566A 2003-10-13 2006-05-12 Formas de dosificación farmacéutica de liberación extendida ECSP066566A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03256438A EP1523979A1 (en) 2003-10-13 2003-10-13 Extended release pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
ECSP066566A true ECSP066566A (es) 2006-10-17

Family

ID=34354596

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006566A ECSP066566A (es) 2003-10-13 2006-05-12 Formas de dosificación farmacéutica de liberación extendida

Country Status (14)

Country Link
US (1) US20050129762A1 (es)
EP (2) EP1523979A1 (es)
KR (1) KR20060108675A (es)
CN (1) CN1889935A (es)
AR (1) AR046102A1 (es)
AU (1) AU2004283436A1 (es)
CA (1) CA2546199A1 (es)
CO (1) CO5690532A2 (es)
CR (1) CR8403A (es)
EC (1) ECSP066566A (es)
NO (1) NO20062142L (es)
PE (1) PE20050439A1 (es)
TW (1) TW200518788A (es)
WO (1) WO2005039527A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
WO2008074145A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
CN101742998B (zh) 2007-03-22 2014-09-17 玛格塞蒂克斯公司 镁组合物及其用途
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
EP2448413A4 (en) * 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL108838C (es) * 1956-03-27
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes

Also Published As

Publication number Publication date
WO2005039527A3 (en) 2006-04-06
WO2005039527A2 (en) 2005-05-06
CO5690532A2 (es) 2006-10-31
EP1523979A1 (en) 2005-04-20
KR20060108675A (ko) 2006-10-18
US20050129762A1 (en) 2005-06-16
NO20062142L (no) 2006-07-06
CA2546199A1 (en) 2005-05-06
CN1889935A (zh) 2007-01-03
AU2004283436A1 (en) 2005-05-06
PE20050439A1 (es) 2005-08-03
AR046102A1 (es) 2005-11-23
EP1675575A2 (en) 2006-07-05
CR8403A (es) 2006-10-26
TW200518788A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
ECSP066566A (es) Formas de dosificación farmacéutica de liberación extendida
DE60333715D1 (de) Verfahren zur Herstellung funktioneller Substrate, die kolumnare Mikrosäulen aufweisen
AR052238A1 (es) Formulacion de tabletas estables
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
BRPI0509184A (pt) composições farmacêuticas
DK2101569T3 (da) Krystallinsk fast rasagilinbase
CR10601A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
UY28572A1 (es) Compuestos novedosos
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
AR048832A1 (es) Tratamiento de soporte de enfermedades hepaticas
CY1108453T1 (el) Διαδικασια για την παρασκευη επλερενονης
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
ECSP066564A (es) Formulaciones de tableta de liberación extendida de venlafaxina
BRPI0509524A (pt) formas cristalinas de n-desmetilclozapina
ECSP066797A (es) Procedimientos para la preparacion de halogenuros de aril- y heteroarilalquilsulfonilo
CR8277A (es) Procedimiento para la sintesis de 6-amino- 4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-3-carbonitrilo
PA8659601A1 (es) Procedimiento para la preparacion de alcoholes aminoetoxibencilicos
WO2008111296A1 (ja) 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬
ITMI20022185A1 (it) Processo per la preparazione di fenolo mediante idrodeossigenazione di benzendioli.
NO20062388L (no) Azitromycin multipartikkulaere doseringsformer
NO20074676L (no) Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid
HN2005030775A (es) Metabolitos de glucuronidos de tigeciclina y epimeros de los mismos
ITMI20041920A1 (it) Processo per la preparazione di n, n-diisopropil-3-2-idrossi-5-metilfenil-3-fenil-propabammina
EA200501262A1 (ru) Композиция с пролонгированным высвобождением венлафаксина